eGene Inc. Will Exhibit at the 2006 Annual Meeting of the American Society of Human Genetics in New Orleans, Louisiana, October 10-13, 2006.IRVINE, Calif. -- eGene Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :EGEI), developer of a revolutionary high-performance genetic analysis technology, today announced that it will exhibit at the 56th annual meeting of The American Society of Human Genetics (ASHG ASHG American Society of Human Genetics ) at the Ernest N. Morial Convention Center The Ernest N. Morial Convention Center is a collection of buildings in New Orleans, Louisiana. The lower end of building one is located 500 m (1640 feet) upriver from Canal Street on the banks of the Mississippi River. Named after former mayor of New Orleans Ernest N. in New Orleans, Louisiana, October 10-13, 2006. The American Society of Human Genetics (ASHG), founded in 1948, is the primary professional membership organization for human geneticists This is a list of people who have made notable contributions to genetics. The growth and development of genetics represents the work of many people. This list of geneticists is therefore by no means complete. Contributors of great distinction to genetics are not yet on the list. in the Americas. The nearly 8,000 members include researchers, academicians, clinicians, laboratory practice professionals, genetic counselors, nurses and others involved in or with special interest in human genetics. Ming S. Liu, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of eGene, made the announcement noting: "Our digital genotyping technology is transforming the genetic analysis field by replacing time-consuming slab gel electrophoresis methods. eGene will attend this meeting to introduce our products to the human genetics society. Our automated HDA-GT12 genetic analyzer has already been used by researchers in different human genetics applications and their works will be presented in this meeting. We believe eGene represents a paradigm shift in the way that scientists think about genetic analysis. Our automatic, affordable, user-friendly genotyping system represents the future of DNA analysis." eGene's Booth Number is 737. The HDA-GT12(TM) Genetic Analyzer is in use at more than 100 hospitals and research centers worldwide. The system analyzes genetic fingerprinting of living organisms through microsatellites, AFLP and RFLP RFLP abbr. restriction fragment length polymorphism RFLP restriction fragment length polymorphism. RFLP . It performs fast DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. sample screening and high-resolution DNA fragment analysis (2-5bp). The system also analyzes the quality and quantity of total RNA RNA: see nucleic acid. RNA in full ribonucleic acid One of the two main types of nucleic acid (the other being DNA), which functions in cellular protein synthesis in all living cells and replaces DNA as the carrier of genetic and cRNA, determines the efficiency of cRNA and cDNA amplification reactions and ensures quality of fragmented cRNA. The company sells cartridges that are specific to the type of analysis to be performed. All data is then received in digital form for appropriate transmission and storage. About eGene Inc. eGene Inc. (www.egeneinc.com) focuses its core technologies of capillary electrophoresis, microfluidics, liquid handling and automation to develop and manufacture low-cost microfluidic, miniaturized digital genetic analyzer systems, software and consumables for biological materials testing applications. These products detect, quantify, identify and characterize DNA and RNA at high rates of specificity and sensitivity while automating routine and non-routine laboratory and industrial procedures critical to product safety, development quality and productivity. This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors. The Company undertakes no obligation to release publicly any revision, which may be made to reflect events or circumstances after the date hereof. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion